Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.|Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
N
N
Lachmann
Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.|Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
K
K
Czarnecki
Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.|Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
S
S
Brennig
Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.|Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
R
R
Phaltane
Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.|Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
M
M
Heise
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
N
N
Heinz
Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
H
H
Kempf
Department of Pediatric Hematology and Oncology, Center for Child and Adolescent Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany.
D
D
Dilloo
Institute of Pharmacology, Research Core Unit Metabolomics, Hannover Medical School, Hannover, Germany.
V
V
Kaever
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.|Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
A
A
Schambach
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
M
M
Heuser
Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.|Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
T
T
Moritz
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D017338:Cladribine / Q000009:adverse effects*; D003561:Cytarabine / Q000009:adverse effects*; D003564:Cytidine Deaminase / Q000502:physiology; D003842:Deoxycytidine Kinase / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D015316:Genetic Therapy; D018922:HL-60 Cells; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D003561:Cytarabine; D017338:Cladribine; D003842:Deoxycytidine Kinase; D003564:Cytidine Deaminase; D014740:Vidarabine; C024352:fludarabine